The Foster City, California-based biotech company said it would generate full year drug sales of $29.6 billion to $30 billion, falling just short of the average estimate from analysts. Adjusted profits will be between $8.45 and $8.85 a share, it said in a statement, with a midpoint below the $8.76 a share average estimate from analysts.
The company could achieve $800 million in sales in 2026 for its new long-acting HIV prevention drug Yeztugo, said Chief Executive Officer ...